Commentary

Not all myocardial infarctions are created equal: The potential of circulating microRNAs to discern coronary artery dissection

Donato Santovito\textsuperscript{a,b,c,*}, Christian Weber\textsuperscript{a,b,d,e,}\textsuperscript{*}

\textsuperscript{a} Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
\textsuperscript{b} Partner Site Munich Heart Alliance (MHA), German Centre for Cardiovascular Research (DZHK), Munich, Germany
\textsuperscript{c} UoS of Milan, National Research Council, Institute for Genetic and Biomedical Research, Milan, Italy
\textsuperscript{d} Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Netherlands
\textsuperscript{e} Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

Article History:
Received 12 April 2021
Accepted 12 April 2021
Available online xxx

Acute myocardial infarction (AMI) is a dramatic manifestation of ischemic heart disease and represents a major cause of mortality worldwide, responsible for over 1 million hospitalizations annually in the United States [1]. Notwithstanding, AMI encompasses different etiopathogenic mechanisms and, although atherothrombosis is the most common one [1], epidemiological evidence accumulates on the relevance of other causes, including spontaneous coronary artery dissection (SCAD). Described for the first time in the early 30s, SCAD is characterized by the development of a hematoma in the media of the coronary artery with delamination of vessel wall and compression of the lumen, thus reducing coronary blood flow to prompt myocardial ischemia. In the light of the different pathogenesis, it is not unexpected that clinical management of acute SCAD and atherothrombotic AMI requires specific considerations as, for example, an invasive treatment strategy (i.e., percutaneous coronary intervention, PCI) results in higher complication rates and less predictable outcomes, whereas conservative management may be preferable in these patients [2,3]. However, the clinical presentation of SCAD is the similar to atherothrombotic AMI, and diagnosis requires experienced interventional cardiologists and invasive approaches such as coronary angiography and optical coherence tomography. Hence, the discovery of easy-to-assess biomarkers for diagnosis of SCAD in patients with symptoms of AMI in emergency settings (e.g., emergency and chest-pain units) would improve their early identification and enable benefits with regards to therapeutic management.

In this article of EBioMedicine, Lozano-Prieto and colleagues report on the diagnostic power of circulating microRNAs for this purpose [4]. MicroRNAs are endogenous short non-coding RNAs with a major influence in the pathogenesis of cardiovascular diseases [5,6]. They are remarkably stable in plasma and serum and have therefore been explored as potential diagnostic or prognostic biomarkers in various diseases including AMI [7]. The authors confirmed that AMI influence the expression of circulating microRNAs and, more importantly, identified and validated a specific microRNA signature able to discern between atherothrombosis or SCAD as the etiology of AMI. Indeed, the simultaneous detection of higher circulating let-7f-5p, miR-146a-5p, miR-151a-3p, and miR-223–5p showed a really good accuracy (C-statistic: 0.88, 95%CI: 0.72–1.00) with 68% positive and 83% negative predictive values for the diagnosis of SCAD across the two independent cohorts in England and Spain, which minimize the possibility of operator- and site-dependent biases.

Not only may circulating microRNAs serve as biomarkers but experimental and clinical studies also suggest that they may mediate a network of intercellular communication by affecting gene expression in recipient cells [6]. For this reason, the authors have explored the possibility that the identified microRNAs could take part in the pathogenesis of SCAD by targeting specific transcripts in cells relevant to the progression of vascular diseases. Indeed, most of the validated targets of the deregulated microRNAs were enriched in processes of blood vessel development, vascular smooth muscle cells proliferation, and TGF-β signaling pathway, which has been implicated in the pathogenesis of SCAD in a recent genetic association study [8]. Interestingly, the genes for the precursors of 2 out of the four regulated microRNAs (MIRLET7F2 and MIR223) are hosted in the X-chromosome, thus potentially contributing to the large prevalence of SCAD in women (87–95% of reported SCAD cases) [2,3,9]. Nonetheless, an inference of a causal role derived from the current study is limited. Although the authors detected differences in circulating levels of some targets (e.g., CXCL8, TGFβ1, MMF2), these results are not consistent with the paradigm of a microRNA-mediated regulation, with targets and microRNAs being concomitantly upregulated. Multiple reasons can explain this apparent paradox, including the

DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2021.103338.
* Corresponding authors at: Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
E-mail addresses: donato.santovito@gmail.com (D. Santovito), chweber@med.lmu.de (C. Weber).

https://doi.org/10.1016/j.ebiom.2021.103366
2352-3964/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
observation that circulating and intracellular pools of microRNAs undergo different regulatory processes, as already reported for let-7f-5p in diabetes [6,10]. Hence, additional experimental studies are warranted to dissect the intimate mechanisms of microRNA regulation of SCAD.

Overall, the study by Lozano-Prieto et al. presents a promising non-invasive tool for diagnosis of SCAD and an attractive standpoint for future large prospective and multicentric clinical trials for a definitive validation of the discriminatory power of the identified microRNA signature. While the lack of standardization in methodology, data normalization and analytical workflows still hamper a rapid adoption of circulating microRNAs as biomarkers in the clinic, their remarkable discriminatory power revealed by studies such as the current one, once confirmed and replicated, will possibly provide the physicians with an important tool for diagnosis of SCAD with the ultimate goal to optimize the clinical management and reduce the complications of invasive therapeutic and diagnostic procedures in those patients.

Declaration of Competing Interest

None

Acknowledgments

The authors are funded by the Deutsche Forschungsgemeinschaft (SFB1123 and TRR267) and European Research Council (ERC AdG ° 692511).

Contributors

DS and CWequally contributed to writing and editing the commentary.